{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Hemophilia+A&page=3", "query": { "condition": "Hemophilia A", "page": 3 }, "page_size": 10 }, "pagination": { "page": 3, "page_size": 10, "total_count": 331, "total_pages": 34, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Hemophilia+A&page=4&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Hemophilia+A&page=2&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-06T20:23:23.735Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01830712", "title": "A Long-term Assessment of Physical Activity, Range of Motion, and Functional Status Following Elective Orthopedic Surgery in Hemophilia Patients With Inhibitors", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Congenital Bleeding Disorder", "Haemophilia A With Inhibitors", "Haemophilia B With Inhibitors" ], "interventions": [ { "name": "eptacog alfa (activated)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novo Nordisk A/S", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "5 Years", "maximum_age": null, "sex": "ALL", "summary": "5 Years and older" }, "enrollment_count": 15, "start_date": "2011-04", "completion_date": "2011-08", "has_results": false, "last_update_posted_date": "2023-12-29", "last_synced_at": "2026-10-06T20:23:23.735Z", "location_count": 1, "location_summary": "Princeton, New Jersey", "locations": [ { "city": "Princeton", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT01830712" }, { "nct_id": "NCT01708564", "title": "A Phase I Safety, Pharmacokinetics and Pharmacodynamics Study of Recombinant Factor VIIa in Adult Patients With Hemophilia A or B", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Hemophilia" ], "interventions": [ { "name": "rhFVIIa", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "rEVO Biologics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "MALE", "summary": "18 Years to 75 Years · Male only" }, "enrollment_count": 15, "start_date": "2012-10", "completion_date": "2013-06", "has_results": false, "last_update_posted_date": "2013-07-30", "last_synced_at": "2026-10-06T20:23:23.735Z", "location_count": 2, "location_summary": "Sacramento, California • Chicago, Illinois", "locations": [ { "city": "Sacramento", "state": "California" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT01708564" }, { "nct_id": "NCT05987449", "title": "A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of NXT007 in Persons With Severe or Moderate Hemophilia A", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Hemophilia A" ], "interventions": [ { "name": "NXT007", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "2 Years", "maximum_age": "59 Years", "sex": "MALE", "summary": "2 Years to 59 Years · Male only" }, "enrollment_count": 60, "start_date": "2023-09-21", "completion_date": "2033-12-11", "has_results": false, "last_update_posted_date": "2026-09-11", "last_synced_at": "2026-10-06T20:23:23.735Z", "location_count": 4, "location_summary": "Sacramento, California • Washington D.C., District of Columbia • Indianapolis, Indiana + 1 more", "locations": [ { "city": "Sacramento", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Indianapolis", "state": "Indiana" }, { "city": "Iowa City", "state": "Iowa" } ], "official_url": "https://clinicaltrials.gov/study/NCT05987449" }, { "nct_id": "NCT05281718", "title": "Factor IX as Adjunctive Therapy to Emicizumab (EMIX)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "Hemophilia A" ], "interventions": [ { "name": "Factor IX", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Tulane University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": "120 Years", "sex": "MALE", "summary": "12 Years to 120 Years · Male only" }, "enrollment_count": 12, "start_date": "2022-08-01", "completion_date": "2024-07-14", "has_results": false, "last_update_posted_date": "2025-01-20", "last_synced_at": "2026-10-06T20:23:23.735Z", "location_count": 2, "location_summary": "Metairie, Louisiana • New Orleans, Louisiana", "locations": [ { "city": "Metairie", "state": "Louisiana" }, { "city": "New Orleans", "state": "Louisiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT05281718" }, { "nct_id": "NCT02585960", "title": "BAX 855 PK-guided Dosing", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Hemophilia A" ], "interventions": [ { "name": "PEGylated Recombinant Factor VIII", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Baxalta now part of Shire", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "12 Years to 65 Years" }, "enrollment_count": 135, "start_date": "2015-11-23", "completion_date": "2018-08-05", "has_results": true, "last_update_posted_date": "2021-05-25", "last_synced_at": "2026-10-06T20:23:23.735Z", "location_count": 14, "location_summary": "Phoenix, Arizona • Tucson, Arizona • Los Angeles, California + 11 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Gainesville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT02585960" }, { "nct_id": "NCT01431326", "title": "Pharmacokinetics of Understudied Drugs Administered to Children Per Standard of Care", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Adenovirus", "Anesthesia", "Anxiety", "Anxiolysis", "Autism", "Autistic Disorder", "Bacterial Meningitis", "Bacterial Septicemia", "Benzodiazepine", "Bipolar Disorder", "Bone and Joint Infections", "Central Nervous System Infections", "Convulsions", "Cytomegalovirus Retinitis", "Early-onset Schizophrenia Spectrum Disorders", "Epilepsy", "General Anesthesia", "Gynecologic Infections", "Herpes Simplex Virus", "Infantile Hemangioma", "Infection", "Inflammation", "Inflammatory Conditions", "Intra-abdominal Infections", "Lower Respiratory Tract Infections", "Migraines", "Pain", "Pneumonia", "Schizophrenia", "Sedation", "Seizures", "Skeletal Muscle Spasms", "Skin and Skin-structure Infections", "Treatment-resistant Schizophrenia", "Urinary Tract Infections", "Withdrawal", "Sepsis", "Gram-negative Infection", "Bradycardia", "Cardiac Arrest", "Cardiac Arrhythmia", "Staphylococcal Infections", "Nosocomial Pneumonia", "Neuromuscular Blockade", "Methicillin Resistant Staphylococcus Aureus", "Endocarditis", "Neutropenia", "Headache", "Fibrinolytic Bleeding", "Pulmonary Arterial Hypertension", "CMV Retinitis", "Hypertension", "Chronic Kidney Diseases", "Hyperaldosteronism", "Hypokalemia", "Heart Failure", "Hemophilia", "Heavy Menstrual Bleeding", "Insomnia" ], "interventions": [ { "name": "The POPS study is collecting PK data on children prescribed the following drugs of interest per standard of care:", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Daniel Benjamin", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "21 Years", "sex": "ALL", "summary": "Up to 21 Years" }, "enrollment_count": 3520, "start_date": "2011-11", "completion_date": "2019-11", "has_results": false, "last_update_posted_date": "2023-09-06", "last_synced_at": "2026-10-06T20:23:23.735Z", "location_count": 43, "location_summary": "Anchorage, Alaska • Little Rock, Arkansas • La Jolla, California + 37 more", "locations": [ { "city": "Anchorage", "state": "Alaska" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01431326" }, { "nct_id": "NCT01138501", "title": "Safety and Efficacy of Turoctocog Alfa in Previously Treated Male Children With Haemophilia A", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Congenital Bleeding Disorder", "Haemophilia A" ], "interventions": [ { "name": "turoctocog alfa", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novo Nordisk A/S", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "11 Years", "sex": "MALE", "summary": "Up to 11 Years · Male only" }, "enrollment_count": 65, "start_date": "2010-06", "completion_date": "2011-11", "has_results": true, "last_update_posted_date": "2017-03-17", "last_synced_at": "2026-10-06T20:23:23.735Z", "location_count": 18, "location_summary": "Phoenix, Arizona • Orange, California • Torrance, California + 15 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Orange", "state": "California" }, { "city": "Torrance", "state": "California" }, { "city": "Tampa", "state": "Florida" }, { "city": "Augusta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT01138501" }, { "nct_id": "NCT02546622", "title": "ATHN 2: Factor Switching Study", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Hemophilia" ], "interventions": [ { "name": "Factor VIII Replacement Products for Hemophilia which were FDA approved after January 1, 2013", "type": "BIOLOGICAL" }, { "name": "Factor IX Replacement Products for Hemophilia which were FDA approved after January 1, 2013", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "American Thrombosis and Hemostasis Network", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 310, "start_date": "2015-09", "completion_date": "2020-06-30", "has_results": false, "last_update_posted_date": "2021-12-09", "last_synced_at": "2026-10-06T20:23:23.735Z", "location_count": 27, "location_summary": "San Diego, California • Aurora, Colorado • New Haven, Connecticut + 23 more", "locations": [ { "city": "San Diego", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "St. Petersburg", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT02546622" }, { "nct_id": "NCT03603275", "title": "Assessing Physician and Hemophilia A Patient Reasons and Expectations for Switching Treatment to Kovaltry & Jivi: A Nested Study Within an Existing Registry", "overall_status": "TERMINATED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Hemophilia A" ], "interventions": [ { "name": "New FVIII products", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bayer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "2 Years", "maximum_age": null, "sex": "ALL", "summary": "2 Years and older" }, "enrollment_count": 3, "start_date": "2018-08-06", "completion_date": "2020-05-14", "has_results": false, "last_update_posted_date": "2022-08-25", "last_synced_at": "2026-10-06T20:23:23.735Z", "location_count": 27, "location_summary": "La Jolla, California • Aurora, Colorado • New Haven, Connecticut + 23 more", "locations": [ { "city": "La Jolla", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "St. Petersburg", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT03603275" }, { "nct_id": "NCT00629837", "title": "Pharmacokinetics and Safety of a Single Intravenous Infusion of BAY 79-4980", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Hemophilia A" ], "interventions": [ { "name": "Recomb. Factor VIII (Kogenate FS Liposome, BAY79-4980)", "type": "BIOLOGICAL" }, { "name": "Recombinant Factor VIII (Kogenate FS, BAY14-2222)", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Bayer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": "60 Years", "sex": "MALE", "summary": "12 Years to 60 Years · Male only" }, "enrollment_count": 27, "start_date": "2005-09", "completion_date": "2006-03", "has_results": false, "last_update_posted_date": "2014-11-18", "last_synced_at": "2026-10-06T20:23:23.735Z", "location_count": 2, "location_summary": "Davis, California • Orange, California", "locations": [ { "city": "Davis", "state": "California" }, { "city": "Orange", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00629837" } ] }